Ovarian, Internal Iliac, and Gonadal Vein Embolization, Ablation, and Sclerotherapy

Effective: August 1, 2020

Next Review: April 2021
Last Review: June 2020

IMPORTANT REMINDER

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

DESCRIPTION

Embolization involves occlusion of blood flow through the ovarian, internal iliac, and gonadal veins with coils, foam, or a chemical sclerosant as a treatment of pelvic congestion syndrome or varicoceles.

MEDICAL POLICY CRITERIA

Note: This policy does not address surgical ligation of the spermatic vein(s) or uterine artery embolization.

I. Embolization, ablation, and sclerotherapy of ovarian veins, internal iliac veins, or gonadal veins is considered investigational for the treatment of the following conditions:
   A. Pelvic congestion syndrome
   B. Varicoceles.

NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.
Enlarged ovarian and internal iliac veins can lead to pelvic congestion syndrome in women, and enlarged gonadal and internal iliac veins can lead to a varicoceles in men. Each are discussed separately below.

**PELVIC CONGESTION SYNDROME**

Pelvic congestion syndrome (PCS), also called pelvic venous incompetence, is a rare condition characterized by chronic pelvic pain. Although this condition is primarily found in women it can also be found in men. PCS is often aggravated by standing for long periods of time, and often manifests during or after pregnancy. The syndrome is thought to be associated with dilated and refluxing incompetent pelvic veins, similar to what happens in varicose veins of the legs. However, the cause of PCS is unclear. Furthermore, there are no definitive diagnostic criteria for PCS. Instead the diagnosis is generally based on a combination of symptoms, tenderness on physical exam, and documentation of pelvic vein dilation or incompetence after excluding all other causes for the nonspecific findings. Although imaging may show vein dilation or incompetence, these findings are common nonspecific findings and therefore no diagnostic.

There is no standard treatment approach for PCS, and the optimum treatment is unknown. Instead, therapy is individualized and based on symptoms. Medical therapy is generally the first line of treatment, as it is low risk and non-invasive. Other methods, such as embolization has been proposed as an alternative to surgical treatment for patients who fail medical therapy with analgesics. Embolization therapy involves the occlusion of blood flow through the ovarian and internal iliac veins with coils, glue, or chemical sclerosants. The internal iliac veins may be treated at the same time or a later date to prevent recurrence.

**VARICOCELES**

A varicocele is the dilation of the pampiniform plexus of the gonadal veins. Varicocele's are present in 15 to 20% of post-pubertal males, and generally get larger over time. Most varicoceles occur in the left hemiscrotum because the left gonadal vein is one of the longest veins in the body and it enters the left renal vein at a perpendicular angle increasing pressure which can dilate the veins and cause incompetence of the valves, similar to what happens in varicose veins of the legs. Although varicoceles on the left are more common, bilateral varicoceles can occur; however, this could be caused by a possible underlying pathology warranting more investigation. Symptoms of a varicocele include dull, aching, left scrotal pain, which is often aggravated by standing for long periods of time, testicular atrophy, and decreased fertility. Although there are no clear guidelines regarding the established treatment for varicoceles, surgical ligation is the preferred first-line treatment.

**EVIDENCE SUMMARY**

The primary beneficial outcomes of interest for treatments of pelvic pain in both men and woman are symptom reduction and improvement in the ability to function. These are subjective outcomes that are typically associated with a placebo effect. Therefore, data from adequately

---

**CROSS REFERENCES**

1. Varicose Vein Treatment, Surgery, Policy No. 104
powered, randomized controlled trials (RCTs) with sufficient long-term follow-up are required to control for the placebo effect, determine its magnitude, and to determine whether any treatment effect from provides a significant advantage over placebo or other treatment options.

**TREATMENT FOR PELVIC CONGESTION SYNDROME**

**Health Technology Assessments**

In 2016, Champaneria published a health technology assessment from the National Institute for Health Research that examined the diagnosis and treatment of pelvic vein incompetence and chronic pelvic pain in women.[1] Forty studies were included in the review; six association studies, ten studies involving ultrasound, two studies involving magnetic resonance venography, 21 case series, and one poor-quality randomized trial of embolization. The authors found that there were no consistent diagnostic criteria for pelvic congestion syndrome (PCS). Although the studies have showed associations between chronic pelvic pain (CPP) and pelvic vein incompetence (PVI), the prevalence of PVI ranged widely. The authors identified that transvaginal ultrasound with doppler and magnetic resonance venography are both useful screening methods; however, there is limited data on the accuracy of these methods for PCS. Finally, although the research showed embolization provides symptomatic relief in the majority of women, these studies were small case series. The authors concluded that more research is needed to determine what the diagnostic criteria for PCS are, and the efficacy of embolization as a treatment for PCS.

**Systematic Reviews**

A 2016 systematic review by Mahmoud identified 20 case series (total N=1081 patients) who underwent vein embolization for pelvic congestion syndrome.[2] The authors did not require any particular diagnostic criteria for pelvic congestion syndrome. The length of follow-up in the studies ranged from one month to six years. Seventeen studies (n=648 patients) reported the proportion of patients who reported symptom relief. Overall, 571 (88.1%) patients reported short-term symptom relief and 77 (11.9%) reported little or no relief. Seventeen studies (n=721 patients) reported symptom relief at 12 months. A total of 88.6% had symptom improvement and 13.4% reported little or no relief. Only one study used a comparison group, but patients in it received conservative treatment because they were ineligible for vein embolization therapy, so outcomes after the two interventions cannot be compared.

A systematic review by Daniels (2016) assessed the effectiveness of sclerotherapy or embolization for the treatment of chronic pelvic pain.[3] The review included 21 case series and one poor-quality randomized trial. Due to the overall low quality and heterogeneity of the studies, a meta-analysis was not performed. However, the authors reported that approximately 75% of women who underwent embolization experienced early pain relief. Adverse events noted included, transient pain following foam embolization and a small (<2%) risk of coil migration.

In 2015 Hansrani published a systematic review that evaluated the effectiveness of transvenous occlusion as a treatment of chronic pelvic pain.[4] Thirteen studies were included comprising 866 women. The authors noted that all 13 studies were of poor methodological quality, and most studies did not use objective outcome measures or have consistent follow-up of outcomes. Studies on embolization for treatment of PCS were rated as poor due to lack of randomization and control groups, unclear patient selection criteria, and heterogeneous outcome measures that did not permit between-study comparison or estimates of overall
treatment effects. There was one RCT included in the review, in which embolization resulted in significantly better pain reduction than hysterectomy, but the study also had significant limitations, including but not limited to, the randomization protocol was not described, and the hysterectomy patients (bilateral compared to unilateral salpingo-oophorectomy) were not blinded to their treatment allocation, small sample size limits the ability to rule out the role of chance as an explanation of study findings, and a discrepancy between reported outcomes in text and data tables. The authors recommended that more high quality studies are needed that compare embolization, with other treatments, including surgical treatments, hormonal therapy, and other noninvasive treatments.

Randomized Controlled Trials

A randomized, prospective trial by Guirola (2018) compared the safety and efficacy of embolization with vascular plugs (VP) or fibered platinum coils (FPC) in women with pelvic congestion syndrome.[5] Patients were enrolled (N=100) and randomly assigned to each treatment group via block randomization (N=50). Diagnosis of pelvic congestion syndrome was accomplished through a symptom screening questionnaire followed by an ultrasound study. Patients with 3 or more positive symptom responses advanced to the ultrasound screening, and patients with pelvic veins >6 mm in diameter and/or venous reflux or dilated midline communicating veins were advanced to randomization. Follow-up screening occurred at 1, 3, 6, and 12 months. The primary outcome was clinical success assessed subjectively through patient responses regarding relief of symptoms and pain scores assessed with the visual analog scale. Clinical success was achieved in 89.7% of the FPC group and 90.6% of the VP group. Improvement in visual analog scale pain scores at the end of 12 months was 90.2% overall and improvement was seen in 95.9% of the FPC group and 96% of the VP group. A total of 11 (22%) complications were seen in the FPC group and 5 (10%) in the VP group. Minor adverse events included access site hematoma and ovarian vein extravasation. Device migrations were considered major complications. A major limitation in the study is the significant difference in age and pre-treatment visual analog scale pain score between groups, both of which were higher in the VP group despite randomization.

Nonrandomized Studies

The remainder of the published literature regarding the clinical outcomes of embolization therapy consists of case series and retrospective reviews.[6-27] Collectively, conclusions concerning safety and effectiveness cannot be reached from these studies due to significant limitations in the data, including but not limited to:

- Lack of established diagnostic criteria for pelvic congestion syndrome. Without consistent criteria for patient selection it is unknown which patients are most likely to benefit, or not benefit, from treatment. Furthermore, it is unknown how results from the various case series can be applied to the overall population of patients with this condition.
- Lack of randomization and comparison groups. Failure to randomize patients to different treatment groups may introduce bias on the part of both the study participant and researchers in favor of the new technology. As noted above, for pain treatments, a comparator (preferably sham treatment) is necessary, in order to guard against this bias and to distinguish treatment from placebo effects.
- Retrospective design and failure to control for other treatments. Retrospective study designs do not allow for control of co-treatments or confounding factors that may influence results. This design may also introduce bias to interpretation of results. Control for
additional factors, such as other medical therapies, is necessary to isolate treatment response to embolization therapy.

- Failure to define relevant study endpoints. Bias may also be introduced by failure to define study endpoints and treatment success prior to commencement of the study.

### Adverse Effects

The following adverse effects associated with embolization of the uterine and internal iliac veins, though uncommon, have been reported in the literature.[6,14]

- Embolization of coils to the pulmonary circulation
- Embolization of coils to the renal circulation
- Accidental embolization of glue fragments
- Perforations of the ovarian vein with extravasation of contrast
- Transient cardiac arrhythmia

### Treatment of Varicoceles

#### Systematic Reviews

In 2012 Kroese published results from a systematic review and meta-analysis that examined the effect of treatment, surgery or embolization, for varicoceles in subfertile men.[28] Ten studies were included in the review, which comprised 894 men. The authors concluded that there is evidence to suggest treatment improves a couple’s chance of pregnancy; however, findings are inconclusive. Furthermore, the available evidence is of low quality and limited to men from couples with subfertility problems. Therefore further research is needed to determine the efficacy of treatment, surgery or embolization, for the treatment of varicoceles.

#### Randomized-Controlled Trials

No randomized controlled trials have been published comparing embolization therapy for the treatment of varicoceles to an alternative or sham/placebo treatment. Randomized controlled trials are especially needed in situations such as this where the primary symptom is pain, a subjective outcome for which a placebo response to treatment is likely.

#### Nonrandomized studies

The remainder of the published literature regarding the clinical outcomes of embolization therapy consists of case series and retrospective reviews.[29-46] Collectively, conclusions concerning safety and effectiveness cannot be reached from these studies due to significant limitations in the data.

### PRACTICE GUIDELINE SUMMARY

#### PELVIC CONGESTION SYNDROME

**American Congress of Obstetricians and Gynecologists**

No relevant policy positions on embolization for treating pelvic congestion syndrome were identified on the American Congress of Obstetricians and Gynecologists (ACOG) website.[47]

**Society for Vascular Surgery (SVS) and the American Venous Forum**
The 2011 Society for Vascular Surgery (SVS) and the American Venous Forum (AVF) guidelines for the care of patients with varicose veins and associated chronic venous diseases provided a Grade 2B recommendation in favor of coil embolization, plugs, or transcatheter sclerotherapy for treatment of PCS. A Grade 2B recommendation is defined as a weak recommendation based on medium quality evidence.[48]

**SUMMARY**

There is not enough research to show that embolization, ablation, or sclerotherapy improves long term health outcomes for people with pelvic congestion syndrome or varicoceles, compared to other forms of therapy. Therefore, embolization, ablation, or sclerotherapy of ovarian veins, internal iliac veins, or gonadal veins are considered investigational for the treatment of pelvic congestion syndrome or varicoceles.

**REFERENCES**


49. Bluecross BlueShield Association Medical Policy Reference Manual "Ovarian and Internal Iliac Vein Embolization as a Treatment of Pelvic Congestion Syndrome." Policy No. 4.01.18

**CODES**

**NOTE:** There are no specific codes for ovarian and internal iliac vein embolization; however, the following codes may be used:

<table>
<thead>
<tr>
<th>Codes</th>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>36012</td>
<td>Selective catheter placement, venous system: second order or more selective, branch (eg, left adrenal vein, petrosal sinus)</td>
</tr>
<tr>
<td></td>
<td>37241</td>
<td>Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; venous, other than hemorrhage (eg, congenital or acquired venous malformations, venous and capillary hemangiomas, varices, varicoceles)</td>
</tr>
<tr>
<td></td>
<td>75894</td>
<td>Transcatheter therapy, embolization, any method, radiological supervision and interpretation</td>
</tr>
<tr>
<td>HCPCS</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

*Date of Origin:* October 2005